VF
IKT icon

Virtu Financial’s Inhibikase Therapeutics IKT Stock Holding History

Virtu Financial’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-24,607
Closed -$41K – 1902
2026
Q1 		$41K Buy
24,607
+1,738
+8% +$3.09K ﹤0.01% 1314
2025
Q4 		$47K Buy
22,869
+9,423
+70% +$15K ﹤0.01% 1313
2025
Q3 		$22K Buy
+13,446
New +$23.3K ﹤0.01% 1268
2023
Q2 		– Sell
-2,245
Closed -$9K – 1739
2023
Q1 		$9K Buy
+2,245
New +$9.37K ﹤0.01% 1357

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Virtu Financial's IKT Position: Q2 2026 in Review

Virtu Financial sold out of Inhibikase Therapeutics (IKT) in Q2 2026, closing a stake of 24,607 shares — an estimated $41K sold.

Virtu Financial first reported a position in IKT in Q1 2023 and held it in 4 quarters. The position peaked at $47K in Q4 2025. 105 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Virtu Financial reported no remaining Inhibikase Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Virtu Financial sold 24,607 Inhibikase Therapeutics shares in Q2 2026, an estimated $41K.
  • Virtu Financial first reported a position in Inhibikase Therapeutics in Q1 2023 and held it in 4 quarters.
  • Virtu Financial's Inhibikase Therapeutics position peaked at $47K in Q4 2025.
  • 105 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.